Morning Briefing
Summaries of health policy coverage from major news organizations
Leukemia Vaccine Succeeds In Pivotal Trial
The Washington Post: Leukemia Vaccine Passes Key Trial, Adding To Breakthrough Year For Cancer Drugs
A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday, marking another positive result in a breakthrough year for cancer vaccines. (Wu, 11/17)
On the abortion pill —
Bloomberg: Abortion Pill Mifepristone Safety Review By FDA Set For March 2027 Completion
US health officials anticipate they will complete a report on the safety of the abortion drug mifepristone by next March, according to an update on the Food and Drug Administration’s website Tuesday. The FDA is using claims data from federal and private health insurance plans to compare the safety of mifepristone use, in combination with another drug called misoprostol, to surgical abortion. The agency expects to obtain the results from its analysis next month. (Edney, 11/17)
More pharma and tech developments —
MedPage Today: FDA Wants Liquid Statin Off Shelves
The FDA wants a liquid formulation of simvastatin (FloLipid) withdrawn from the market, though the agency is giving the drugmaker an opportunity for a hearing. Approval of simvastatin oral suspension is at risk because Salerno Pharma "has repeatedly failed to file required annual reports" to the FDA, according to a notice in the Federal Register. (Lou, 11/17)
The New York Times: Fearing Chinese Rivals, U.S. Biotech Adopts A New Norm: Share Nothing
It used to be that companies and scientists with ideas for new drugs couldn’t wait to announce their discoveries at meetings, in preprints and on their websites. That is changing. Researchers at the biotechnology firm Alnylam Pharmaceuticals have an unwritten policy: Do not reveal early-stage studies or discuss unpublished data, according to its founding chief executive, Dr. Christoph Westphal. (Kolata, 11/17)
Stat: New Startup Wants To Treat Sickle Cell Anemia Without Gene Therapy
For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks. Biotech entrepreneur Romesh Subramanian thinks he might have one. (Mast, 11/17)
The New York Times: What Can Genes Reveal About Chronic Pain?
Nearly everyone knows someone living with chronic pain. Yet this condition remains notoriously difficult to measure, explain or treat. It can follow an acute injury or arrive unprompted, often evading medical scans and leaving patients without the visible evidence that might convince others their pain is real. And doctors still struggle to understand why pain lingers indefinitely in some bodies and dissipates in others. (Baumgaertner Nunn, 11/17)
The New York Times: Does This Man Have A Right To The Data From His Own Brain?
On a recent Thursday, J. Galen Buckwalter drove 15 minutes from his home to the California Institute of Technology, steered his wheelchair into a laboratory and, as he had twice a week for two years, plugged in his brain. More precisely, he allowed a researcher to attach wires to three metal knobs screwed into his skull like a cyberpunk mohawk. The wires connect to six chips that were implanted in his brain during a seven-hour craniotomy. They record his neural signals — the firing of his brain when he thinks, speaks or moves — and transmit them to a computer to be analyzed. (Wang, 11/17)